Hacker-City
Hacker-City
Get the brief
Health|May 25, 2026|1 min read

Eli Lilly Reports Phase 1 Trial Data for VERV-102 Gene Editing Therapy Targeting Cholesterol

Eli Lilly has released Phase 1 trial data for VERV-102, a gene editing therapeutic designed to reduce cholesterol levels by targeting specific genetic pathways. The preliminary results represent a significant step forward in developing gene-based treatments for cardiovascular disease.

#eli-lilly#verv-102#gene-editing#cholesterol#phase-1-trial#cardiovascular-disease#genetic-therapy#clinical-trial#biotech#drug-development
S

Stat News

Contributor

Share this story

Next story

Eli Lilly's Gene-Editing Approach Shows Promise in Early Cholesterol Trial

Eli Lilly's experimental gene-editing therapy demonstrates early efficacy in Phase 1 trials for cholesterol management, marking a significant advancement in genetic treatment approaches.